X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (14600) 14600
Newsletter (79) 79
Newspaper Article (68) 68
Magazine Article (47) 47
Book Chapter (14) 14
Transcript (12) 12
Dissertation (6) 6
Book Review (4) 4
Publication (4) 4
Reference (4) 4
Government Document (2) 2
Book / eBook (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (9672) 9672
male (7537) 7537
animals (5817) 5817
sulfonamides - administration & dosage (5602) 5602
female (5501) 5501
sulfonamides - pharmacology (4609) 4609
sulfonamides - therapeutic use (4469) 4469
middle aged (3598) 3598
adult (3004) 3004
pharmacology & pharmacy (2841) 2841
aged (2706) 2706
sulfonamides - adverse effects (2493) 2493
rats (2391) 2391
treatment outcome (2014) 2014
mice (1890) 1890
celecoxib (1790) 1790
sulfonamides (1764) 1764
dose-response relationship, drug (1536) 1536
oncology (1515) 1515
drug therapy, combination (1360) 1360
sulfonamides - pharmacokinetics (1348) 1348
administration, oral (1302) 1302
analysis (1094) 1094
time factors (1014) 1014
drug therapy (980) 980
rats, sprague-dawley (973) 973
research (970) 970
expression (955) 955
care and treatment (952) 952
double-blind method (942) 942
cancer (925) 925
rosuvastatin calcium (873) 873
disease models, animal (864) 864
pyrimidines - administration & dosage (837) 837
therapy (827) 827
aged, 80 and over (825) 825
pyrimidines - therapeutic use (787) 787
drug administration schedule (778) 778
pharmacokinetics (773) 773
efficacy (769) 769
dosage and administration (765) 765
medicine & public health (757) 757
cardiac & cardiovascular systems (751) 751
adolescent (741) 741
cell line, tumor (716) 716
sulfonamides - chemistry (709) 709
apoptosis (706) 706
rats, wistar (693) 693
safety (660) 660
prospective studies (651) 651
pyrazoles - administration & dosage (640) 640
health aspects (633) 633
biochemistry & molecular biology (610) 610
neurosciences (605) 605
medicine, general & internal (587) 587
drug interactions (576) 576
pyrazoles - pharmacology (576) 576
inflammation (555) 555
cyclooxygenase inhibitors - pharmacology (545) 545
drugs (541) 541
young adult (532) 532
pharmacology/toxicology (527) 527
abridged index medicus (525) 525
apoptosis - drug effects (525) 525
risk factors (518) 518
sulfonamides - blood (514) 514
dogs (502) 502
pyrazoles - therapeutic use (498) 498
pharmacology (494) 494
inhibition (486) 486
clinical trials (484) 484
ophthalmology (481) 481
bosentan (478) 478
activation (474) 474
drug synergism (473) 473
research article (465) 465
nonsteroidal antiinflammatory drugs (463) 463
hiv infections - drug therapy (462) 462
chemistry, medicinal (461) 461
double-blind (459) 459
cell biology (455) 455
internal medicine (454) 454
follow-up studies (452) 452
intraocular pressure - drug effects (452) 452
retrospective studies (452) 452
antineoplastic combined chemotherapy protocols - therapeutic use (451) 451
cyclooxygenase 2 (450) 450
drug combinations (448) 448
medicine, research & experimental (446) 446
rosuvastatin (443) 443
cox-2 inhibitors (442) 442
mutation (440) 440
immunology (438) 438
mice, inbred c57bl (438) 438
pyrimidines - pharmacology (438) 438
cells (437) 437
proteins (436) 436
hypertension (433) 433
in-vitro (432) 432
fluorobenzenes - administration & dosage (424) 424
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (13976) 13976
German (265) 265
Japanese (217) 217
French (136) 136
Russian (106) 106
Italian (71) 71
Spanish (57) 57
Chinese (47) 47
Polish (19) 19
Portuguese (17) 17
Danish (15) 15
Romanian (15) 15
Czech (13) 13
Hungarian (13) 13
Dutch (10) 10
Norwegian (9) 9
Swedish (9) 9
Slovak (8) 8
Bulgarian (5) 5
Croatian (5) 5
Turkish (4) 4
Ukrainian (4) 4
Hebrew (2) 2
Korean (2) 2
Serbian (2) 2
Finnish (1) 1
Lithuanian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


JAMA : the journal of the American Medical Association, ISSN 0098-7484, 05/2014, Volume 311, Issue 18, pp. 1870 - 1882
Journal Article
Journal of Hepatology, ISSN 0168-8278, 2015, Volume 63, Issue 6, pp. 1511 - 1522
Summary Failure to respond to the approved combinations of multiple direct-acting antiviral agents is relatively low in hepatitis C virus treatment... 
Gastroenterology and Hepatology | Daclatasvir | Simeprevir | Treatment | Resistance-associated variants | Ledipasvir | Interferon | Hepatitis C virus | Sofosbuvir | Direct-acting antivirals | Resistanceassociated variants | CHRONIC HCV | CHRONIC HEPATITIS-C | REAL-WORLD | PEGYLATED INTERFERON | DOUBLE-BLIND | GENOTYPE 1 INFECTION | INTERFERON-ALPHA 2A | GASTROENTEROLOGY & HEPATOLOGY | TREATMENT-NAIVE PATIENTS | DACLATASVIR PLUS SOFOSBUVIR | Uridine Monophosphate - administration & dosage | Humans | Hepacivirus - genetics | Hepatitis C, Chronic - virology | Imidazoles - administration & dosage | Carbamates - administration & dosage | Simeprevir - administration & dosage | Uracil - administration & dosage | Benzimidazoles - administration & dosage | Ribavirin - administration & dosage | Treatment Failure | Protease Inhibitors - administration & dosage | Fluorenes - administration & dosage | Drug Therapy, Combination | Hepacivirus - drug effects | Antiviral Agents - therapeutic use | Clinical Trials as Topic | Hepatitis C, Chronic - drug therapy | Antiviral Agents - administration & dosage | Interferons - administration & dosage | Drug Resistance, Viral - genetics | Anilides - administration & dosage | Sofosbuvir - administration & dosage | Uridine Monophosphate - analogs & derivatives | Macrocyclic Compounds - administration & dosage | Sulfonamides - administration & dosage | Uracil - analogs & derivatives | Development and progression | Protease inhibitors | Drug resistance | Hepatitis C | Proteases
Journal Article
Gastroenterology, ISSN 0016-5085, 2016, Volume 151, Issue 3, pp. 457 - 471.e5
Journal Article
British Journal of Clinical Pharmacology, ISSN 0306-5251, 08/2012, Volume 74, Issue 2, pp. 336 - 345
...). However, the potential for drug interactions with co‐administration of GSK2248761 and other antiretroviral medications or supportive medications is not known... 
NNRTI | HIV‐1 infection | antiretroviral therapy | drug‐drug interaction | HIV-1 infection | Drug-drug interaction | Antiretroviral therapy | PHARMACOKINETICS | TOLERABILITY | PHARMACOLOGY & PHARMACY | ATAZANAVIR | SIMVASTATIN | drug-drug interaction | PROTEASE INHIBITORS | Fluorobenzenes - pharmacokinetics | Pyrroles - pharmacokinetics | Darunavir | Ethinyl Estradiol - pharmacokinetics | Humans | Pyrrolidinones - pharmacokinetics | Male | Fluorobenzenes - administration & dosage | Indoles - administration & dosage | Lopinavir - pharmacokinetics | Anti-HIV Agents - administration & dosage | Pyrrolidinones - administration & dosage | Tenofovir | Deoxycytidine - pharmacokinetics | Drug Interactions | Pyrroles - administration & dosage | Contraceptives, Oral - administration & dosage | Patient Safety | Atazanavir Sulfate | Contraceptives, Oral - pharmacokinetics | Phosphinic Acids - administration & dosage | Raltegravir Potassium | Emtricitabine | Adenine - analogs & derivatives | Pyridines - administration & dosage | Risk Assessment | Simvastatin - administration & dosage | Deoxycytidine - administration & dosage | Phosphinic Acids - pharmacokinetics | Rosuvastatin Calcium | Adenine - pharmacokinetics | Sulfonamides - pharmacokinetics | Cross-Over Studies | Cytochrome P-450 CYP3A - metabolism | Atorvastatin | Cytochrome P-450 CYP2D6 - metabolism | Least-Squares Analysis | Lopinavir - administration & dosage | Pyrimidines - pharmacokinetics | Oligopeptides - administration & dosage | Deoxycytidine - analogs & derivatives | Sulfonamides - administration & dosage | Cytochrome P-450 CYP2D6 Inhibitors | Hydroxymethylglutaryl-CoA Reductase Inhibitors - administration & dosage | Heptanoic Acids - pharmacokinetics | Pyridines - pharmacokinetics | Reverse Transcriptase Inhibitors - administration & dosage | Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacokinetics | Reverse Transcriptase Inhibitors - pharmacokinetics | Heptanoic Acids - administration & dosage | Female | Ethinyl Estradiol - administration & dosage | Androstenes - pharmacokinetics | Double-Blind Method | Ritonavir - administration & dosage | Pyrimidines - administration & dosage | Oligopeptides - pharmacokinetics | Linear Models | Simvastatin - pharmacokinetics | Androstenes - administration & dosage | Adenine - administration & dosage | Organophosphonates - pharmacokinetics | Organophosphonates - administration & dosage | Cytochrome P-450 CYP3A Inhibitors | Ritonavir - pharmacokinetics | Anti-HIV Agents - pharmacokinetics | Indoles - pharmacokinetics | Drug Combinations | Urine | Simvastatin | Drug interactions | Cytochrome P-450 | HIV (Viruses) | Complications and side effects | Analysis | Electrocardiogram | Electrocardiography | DNA polymerases | Ethinyl estradiol | Dosage and administration | EKG | Antiviral agents | Urinalysis | Ritonavir | tenofovir | Cytochrome P450 | Lopinavir | ethinylestradiol | Blood | Infection | non-nucleoside reverse transcriptase inhibitors | Antiviral activity | Drug interaction | Probes | CYP2D6 protein
Journal Article
The Journal of Bone & Joint Surgery, ISSN 0021-9355, 02/2013, Volume 95, Issue 4, pp. 291 - 296
BACKGROUND:Appropriate pain management affects outcome after hip fracture surgery. Although multimodal pain management is commonly used for pain control for... 
KNEE | SURGERY | DEMENTIA | TOTAL JOINT ARTHROPLASTY | DELIRIUM | HOSPITAL STAY | LOCAL INFILTRATION ANALGESIA | ELDERLY PATIENTS | ORTHOPEDICS | PUMP | CONSUMPTION | POSTOPERATIVE PAIN | Fentanyl - administration & dosage | Single-Blind Method | Hip Fractures - surgery | Pyrazoles - therapeutic use | Prospective Studies | Fentanyl - therapeutic use | Humans | Male | Adrenergic alpha-Agonists - therapeutic use | Arthroplasty, Replacement, Hip - methods | Adrenergic alpha-Agonists - administration & dosage | Epinephrine - therapeutic use | Cyclooxygenase 2 Inhibitors - therapeutic use | Statistics, Nonparametric | Aged, 80 and over | Anesthetics, Local - therapeutic use | Anesthetics, Local - administration & dosage | Oxycodone - therapeutic use | Oxycodone - administration & dosage | Cyclooxygenase 2 Inhibitors - administration & dosage | Pain Management - methods | Analgesics, Opioid - therapeutic use | Anti-Bacterial Agents - administration & dosage | Morphine - administration & dosage | Sulfonamides - administration & dosage | Ketorolac - therapeutic use | Pain, Postoperative - drug therapy | Epinephrine - administration & dosage | Patient Satisfaction | Anti-Bacterial Agents - therapeutic use | Cefmetazole - therapeutic use | Female | Drug Therapy, Combination | Analgesia, Patient-Controlled | Treatment Outcome | Amides - therapeutic use | Celecoxib | Chi-Square Distribution | Pyrazoles - administration & dosage | Sulfonamides - therapeutic use | Analgesics, Opioid - administration & dosage | Anti-Inflammatory Agents, Non-Steroidal - therapeutic use | Anti-Inflammatory Agents, Non-Steroidal - administration & dosage | Injections, Intra-Articular | Aged | Ketorolac - administration & dosage | Pain Measurement | Amides - administration & dosage | Morphine - therapeutic use | Cefmetazole - administration & dosage
Journal Article
Journal of Hepatology, ISSN 0168-8278, 2017, Volume 66, Issue 6, pp. 1138 - 1148
Graphical abstract 
Gastroenterology and Hepatology | Antiviral agents | Ombitasvir | Ritonavir | Ledipasvir | Real-world | Genotype 1 | Paritaprevir | Sustained virologic response | Hepatitis C, Chronic | Sofosbuvir | Dasabuvir | Randomized controlled trials | PLUS RIBAVIRIN | VIRUS-INFECTION | CHRONIC HEPATITIS-C | SUSTAINED VIROLOGICAL RESPONSE | ALL-CAUSE MORTALITY | Chronic | HEPATOCELLULAR-CARCINOMA | TREATMENT-EXPERIENCED PATIENTS | Hepatitis C | GASTROENTEROLOGY & HEPATOLOGY | Uridine Monophosphate - administration & dosage | Humans | Middle Aged | Hepatitis C, Chronic - physiopathology | Hepacivirus - genetics | Hepatitis C, Chronic - virology | Male | Carbamates - administration & dosage | Neoplasm Recurrence, Local - etiology | Liver Neoplasms - etiology | Young Adult | Uracil - administration & dosage | Benzimidazoles - administration & dosage | Ribavirin - administration & dosage | Aged, 80 and over | Adult | Female | Fluorenes - administration & dosage | Carcinoma, Hepatocellular - etiology | Retrospective Studies | Drug Therapy, Combination | Glomerular Filtration Rate | Ritonavir - administration & dosage | Antiviral Agents - therapeutic use | Genotype | Treatment Outcome | Hepatitis C, Chronic - drug therapy | Antiviral Agents - administration & dosage | Spain | Anilides - administration & dosage | Antiviral Agents - adverse effects | Uridine Monophosphate - analogs & derivatives | Aged | Macrocyclic Compounds - administration & dosage | Sustained Virologic Response | Sulfonamides - administration & dosage | Cohort Studies | Uracil - analogs & derivatives | Genetic aspects | Safety and security measures | Hepatitis C virus
Journal Article
Japanese Journal of Clinical Oncology, ISSN 0368-2811, 05/2015, Volume 45, Issue 5, pp. 408 - 410
Several 'lines of therapy' that utilize cytotoxic agents and are driven by platinum-free intervals are the current standard of care for patients with recurrent... 
Chemo-gynecology | Molecular Dx | Gynecol-med | PEGYLATED LIPOSOMAL DOXORUBICIN | CARBOPLATIN | gynecol-med | BEVACIZUMAB | molecular Dx | COMBINATION | CHEMOTHERAPY | PACLITAXEL | PHASE-III TRIAL | THERAPY | ONCOLOGY | DOUBLE-BLIND | PROGRESSION | chemo-gynecology | Piperazines - administration & dosage | Humans | Neoplasm Recurrence, Local - drug therapy | Antineoplastic Agents - therapeutic use | Folic Acid - administration & dosage | TOR Serine-Threonine Kinases - antagonists & inhibitors | Antibodies, Monoclonal, Humanized - administration & dosage | Vinca Alkaloids - administration & dosage | Benzimidazoles - administration & dosage | Doxorubicin - analogs & derivatives | Angiogenesis Inhibitors - therapeutic use | Antimetabolites, Antineoplastic - pharmacology | Female | Quinazolines - administration & dosage | Antineoplastic Agents - pharmacology | Paclitaxel - administration & dosage | Everolimus | Ovarian Neoplasms - drug therapy | Recombinant Fusion Proteins - administration & dosage | Doxorubicin - administration & dosage | Sirolimus - analogs & derivatives | Folic Acid - analogs & derivatives | Phthalazines - administration & dosage | Pyrimidines - administration & dosage | Deoxycytidine - administration & dosage | Angiogenesis Inhibitors - pharmacology | Carboplatin - administration & dosage | Poly(ADP-ribose) Polymerase Inhibitors | Polyethylene Glycols - administration & dosage | Sirolimus - administration & dosage | Antimetabolites, Antineoplastic - therapeutic use | Antibodies, Monoclonal - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Nivolumab | Neoplasms, Glandular and Epithelial - drug therapy | Carcinoma, Ovarian Epithelial | Topotecan - administration & dosage | Deoxycytidine - analogs & derivatives | Sulfonamides - administration & dosage
Journal Article
The lancet oncology, ISSN 1470-2045, 2015, Volume 16, Issue 13, pp. 1389 - 1398
Summary Background In the COMBI-v trial, patients with previously untreated BRAF Val600Glu or Val600Lys mutant unresectable or metastatic melanoma who were... 
Hematology, Oncology and Palliative Medicine | SURVIVAL | EQ-5D | QUESTIONNAIRE QLQ-C30 | ONCOLOGY | SCORES | RELIABILITY | EUROPEAN-ORGANIZATION | CANCER | VALIDITY | Prospective Studies | Skin Neoplasms - drug therapy | Oximes - adverse effects | Humans | Oximes - administration & dosage | Protein Kinase Inhibitors - adverse effects | Indoles - administration & dosage | Time Factors | DNA Mutational Analysis | Imidazoles - therapeutic use | MAP Kinase Kinase Kinases - antagonists & inhibitors | Genetic Predisposition to Disease | Administration, Oral | Imidazoles - adverse effects | Pyrimidinones - adverse effects | Pyrimidinones - therapeutic use | Risk Factors | MAP Kinase Kinase Kinases - metabolism | Disease Progression | Proto-Oncogene Proteins B-raf - antagonists & inhibitors | Protein Kinase Inhibitors - administration & dosage | Phenotype | Indoles - adverse effects | Intention to Treat Analysis | Quality of Life | Indoles - therapeutic use | Biomarkers, Tumor - genetics | Pyrimidinones - administration & dosage | Mutation | Sulfonamides - administration & dosage | Melanoma - mortality | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Imidazoles - administration & dosage | Oximes - therapeutic use | Pyridones - administration & dosage | Melanoma - genetics | Skin Neoplasms - mortality | Surveys and Questionnaires | Skin Neoplasms - pathology | Drug Administration Schedule | Treatment Outcome | Melanoma - secondary | Disease-Free Survival | Sulfonamides - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Proto-Oncogene Proteins B-raf - genetics | Melanoma - drug therapy | Skin Neoplasms - genetics | Sulfonamides - adverse effects | Pyridones - therapeutic use | Pyridones - adverse effects | Care and treatment | Hospitals | Metastasis | Gene mutations | Comparative analysis
Journal Article
Gut, ISSN 0017-5749, 09/2016, Volume 65, Issue 9, pp. 1439 - 1446
ObjectiveThe objective of this study was to assess the efficacy, safety and tolerability of vonoprazan, a novel potassium-competitive acid blocker, as a... 
antibiotic therapy | clinical trials | Helicobacter pylori infection | helicobacter pylori - treatment | CLARITHROMYCIN | LANSOPRAZOLE | MULTICENTER | MANAGEMENT | CLINICAL-TRIAL | PHARMACOKINETICS | JAPAN | INFECTION | MONOFUMARATE TAK-438 | GASTROENTEROLOGY & HEPATOLOGY | AMOXICILLIN | Humans | Middle Aged | Helicobacter Infections - complications | Helicobacter pylori - drug effects | Male | Drug Monitoring - methods | Proton Pump Inhibitors - administration & dosage | Pyrroles - administration & dosage | Helicobacter Infections - drug therapy | Clarithromycin - administration & dosage | Metronidazole - adverse effects | Peptic Ulcer - diagnosis | Pyrroles - adverse effects | Adult | Female | Amoxicillin - administration & dosage | Anti-Bacterial Agents - adverse effects | Helicobacter Infections - diagnosis | Lansoprazole - administration & dosage | Proton Pump Inhibitors - adverse effects | Double-Blind Method | Drug Administration Schedule | Clarithromycin - adverse effects | Metronidazole - administration & dosage | Treatment Outcome | Drug Therapy, Combination - methods | Lansoprazole - adverse effects | Sulfonamides - adverse effects | Amoxicillin - adverse effects | Helicobacter pylori - isolation & purification | Anti-Bacterial Agents - administration & dosage | Peptic Ulcer - drug therapy | Breath Tests - methods | Peptic Ulcer - etiology | Sulfonamides - administration & dosage | Usage | Safety and security measures | Research | Helicobacter pylori | Antacids | Helicobacter Pylori | HELICOBACTER PYLORI - TREATMENT | CLINICAL TRIALS | 1506 | ANTIBIOTIC THERAPY | HELICOBACTER PYLORI INFECTION
Journal Article
Cochrane Database of Systematic Reviews, ISSN 1469-493X, 02/2018, Volume 2019, Issue 4, p. CD004121
Background This is an updated version of the original Cochrane review published in 2014, Issue 4. Cervical intraepithelial neoplasia (CIN) precedes the... 
Uterine Cervical Neoplasms | Administration, Oral | Anti‐Inflammatory Agents, Non‐Steroidal | CANCER OF THE UTERINE CERVIX | Induction Chemotherapy | Celecoxib | Cervix | Disease Progression | Lactones | Randomized Controlled Trials as Topic | Gynaecology | Cyclooxygenase 2 Inhibitors | Sulfonamides | Gynaecological | Placebos | Medicine General & Introductory Medical Sciences | Cervical Intraepithelial Neoplasia | Sulfones | Strategies and implementation for pre‐malignant changes | Cancer | COX-2 | Sulfones [administration & dosage; therapeutic use] | Humans | Sulfonamides [administration & dosage; therapeutic use] | COLON-CANCER | MEDICINE, GENERAL & INTERNAL | PHASE-II TRIAL | CHEMOPREVENTIVE ACTIVITY | TRANSITIONAL-CELL CARCINOMA | Pyrazoles [administration & dosage; therapeutic use] | Female | Lactones [administration & dosage; therapeutic use] | INHIBITOR | UP-REGULATION | Uterine Cervical Neoplasms [drug therapy] | Induction Chemotherapy [methods] | DOUBLE-BLIND | Cyclooxygenase 2 Inhibitors [administration & dosage; therapeutic use] | CYCLOOXYGENASE-2 EXPRESSION | Anti-Inflammatory Agents, Non-Steroidal [administration & dosage; therapeutic use] | Cervical Intraepithelial Neoplasia [drug therapy] | Sulfones - therapeutic use | Cervical Intraepithelial Neoplasia - pathology | Cyclooxygenase 2 Inhibitors - administration & dosage | Induction Chemotherapy - methods | Cervical Intraepithelial Neoplasia - drug therapy | Uterine Cervical Neoplasms - drug therapy | Uterine Cervical Neoplasms - pathology | Celecoxib - therapeutic use | Lactones - therapeutic use | Placebos - therapeutic use | Sulfonamides - therapeutic use | Anti-Inflammatory Agents, Non-Steroidal - therapeutic use | Lactones - administration & dosage | Anti-Inflammatory Agents, Non-Steroidal - administration & dosage | Cyclooxygenase 2 Inhibitors - therapeutic use | Adult | Sulfonamides - administration & dosage | Sulfones - administration & dosage
Journal Article
Lancet, The, ISSN 0140-6736, 2014, Volume 384, Issue 9941, pp. 403 - 413
Journal Article